Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
33.30
-0.16 (-0.48%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.57 - 35.99
52 week 23.94 - 40.21
Open 35.52
Vol / Avg. 1.74M/424,976.00
Mkt cap 1.89B
P/E     -
Div/yield     -
EPS -1.27
Shares 57.11M
Beta 1.33
Inst. own 107%
May 12, 2016
Insulet Corp Annual Shareholders Meeting (Estimated) - 8:30AM EDT - Add to calendar
May 11, 2016
Insulet Corp Annual Shareholders Meeting - 8:30AM EDT - Add to calendar
Apr 28, 2016
Q1 2016 Insulet Corp Earnings Call
Apr 28, 2016
Q1 2016 Insulet Corp Earnings Release
Mar 7, 2016
Insulet Corp at Raymond James Institutional Investors Conference
Feb 25, 2016
Q4 2015 Insulet Corp Earnings Call - Webcast
Feb 25, 2016
Q4 2015 Insulet Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -27.29% -22.68%
Operating margin -24.01% -18.74%
EBITD margin - -13.86%
Return on average assets -38.58% -25.69%
Return on average equity -245.80% -124.74%
Employees 647 -
CDP Score - -

Address

600 Technology Park Dr Ste 200
BILLERICA, MA 01821-4126
United States - Map
+1-978-6007000 (Phone)
+1-978-6000120 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Company’s principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.

Officers and directors

Michael L. Levitz Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Daniel J. Levangie President - Insulet Drug Delivery
Age: 64
Bio & Compensation  - Reuters
Shacey Petrovic President -- Insulet Diabetes Products
Age: 41
Bio & Compensation  - Reuters
Bradley Thomas CFA Executive Vice President - Human Resources & Organizational Development
Age: 57
Bio & Compensation  - Reuters
Mark Licari Vice President - Global Manufacturing and Operations
Bio & Compensation  - Reuters
David Colleran J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Patrick J. Sullivan President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
John A. Fallon M.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Jessica Hopfield Director
Bio & Compensation  - Reuters
Charles T. Liamos Director
Age: 55
Bio & Compensation  - Reuters